Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.
Am J Psychiatry
; 158(10): 1722-5, 2001 Oct.
Article
em En
| MEDLINE
| ID: mdl-11579010
ABSTRACT
OBJECTIVE:
The goal of this study was to evaluate the effects of the addition of tandospirone, a serotonin-1A (5-HT(1A)) agonist, to ongoing treatment with typical antipsychotic drugs, on two cognitive domains that are relevant to functional outcome in patients with schizophrenia.METHOD:
Twenty-six patients with schizophrenia who were receiving stable doses of typical antipsychotics were randomly assigned to adjunctive treatment with 30 mg/day of tandospirone or placebo for 6 weeks. Executive function and verbal memory as well as psychopathology were assessed at baseline and after 6 weeks.RESULTS:
Both cognitive measures improved significantly in the patients who received tandospirone; subjects who did not receive tandospirone showed no change. There was no significant change in psychopathology ratings in either group.CONCLUSIONS:
The results suggest the usefulness of 5-HT(1A) agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Piperazinas
/
Pirimidinas
/
Esquizofrenia
/
Antipsicóticos
/
Agonistas do Receptor de Serotonina
/
Transtornos Cognitivos
Tipo de estudo:
Clinical_trials
Limite:
Humans
Idioma:
En
Ano de publicação:
2001
Tipo de documento:
Article